Several preclinical experiments have shown that the single or combined use of mTOR inhibitors can significantly inhibit tumor growth, increase cell sensitivity to TKIs, and even reverse drug resistance (Lin et al. 2017; Zheng et al. 2015). This evidence concerns the gene MTOR and neoplasm.